[go: up one dir, main page]

MA42303A - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques

Info

Publication number
MA42303A
MA42303A MA042303A MA42303A MA42303A MA 42303 A MA42303 A MA 42303A MA 042303 A MA042303 A MA 042303A MA 42303 A MA42303 A MA 42303A MA 42303 A MA42303 A MA 42303A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
MA042303A
Other languages
English (en)
Inventor
Joanna Koziara
Diana Sperger
Original Assignee
Gilead Sciences Inc
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Janssen Sciences Ireland Uc filed Critical Gilead Sciences Inc
Publication of MA42303A publication Critical patent/MA42303A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA042303A 2015-06-30 2016-06-28 Formulations pharmaceutiques MA42303A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187102P 2015-06-30 2015-06-30
US201662296524P 2016-02-17 2016-02-17

Publications (1)

Publication Number Publication Date
MA42303A true MA42303A (fr) 2018-05-09

Family

ID=56413867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042303A MA42303A (fr) 2015-06-30 2016-06-28 Formulations pharmaceutiques

Country Status (16)

Country Link
US (1) US20170027967A1 (fr)
EP (1) EP3316869A1 (fr)
JP (2) JP2018519325A (fr)
KR (2) KR20200037880A (fr)
CN (1) CN107921003A (fr)
AU (1) AU2016285916B9 (fr)
BR (1) BR112017028140A2 (fr)
CA (1) CA2921336A1 (fr)
EA (1) EA201792591A1 (fr)
HK (2) HK1252156A1 (fr)
IL (1) IL256491A (fr)
MA (1) MA42303A (fr)
MX (1) MX2017016802A (fr)
NZ (1) NZ738524A (fr)
SG (1) SG10201912530XA (fr)
WO (1) WO2017004012A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3608325T3 (pl) 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
CA3077624A1 (fr) * 2016-10-01 2018-04-05 James Smeeding Compositions pharmaceutiques comprenant une statine et un cannabinoide et leurs utilisations
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
WO2019191008A1 (fr) * 2018-03-25 2019-10-03 Biohaven Pharmaceutical Holding Company Ltd. Rimegepant pour troubles liés au cgrp
KR102281373B1 (ko) 2018-04-26 2021-07-22 주식회사 엘지에너지솔루션 고체 전해질 전지용 양극 및 그를 포함하는 고체 전해질 전지
KR102016952B1 (ko) * 2019-04-19 2019-09-02 유니셀랩 주식회사 신규한 결정형 형태의 항바이러스제 및 이의 제조방법
CA3144534A1 (fr) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Procedes de traitement du vih chez des patients pediatriques par la rilpivirine
WO2021015818A1 (fr) * 2019-07-19 2021-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prophylaxie pré-exposition du vih
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501002A1 (en) * 2010-11-19 2013-09-09 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
MD20140091A2 (ro) * 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
WO2015022351A1 (fr) * 2013-08-14 2015-02-19 Ratiopharm Gmbh Médicament comprenant une association pharmaceutique de dolutégravir, d'emtricitabine et de ténofovir

Also Published As

Publication number Publication date
AU2016285916A1 (en) 2018-01-18
MX2017016802A (es) 2018-09-06
KR20200037880A (ko) 2020-04-09
WO2017004012A1 (fr) 2017-01-05
US20170027967A1 (en) 2017-02-02
SG10201912530XA (en) 2020-02-27
JP2019116514A (ja) 2019-07-18
BR112017028140A2 (pt) 2018-08-28
AU2016285916B9 (en) 2019-04-04
NZ738524A (en) 2019-02-22
IL256491A (en) 2018-02-28
KR20180048584A (ko) 2018-05-10
AU2016285916B2 (en) 2019-03-07
JP2018519325A (ja) 2018-07-19
CA2921336A1 (fr) 2016-12-30
HK1252156A1 (zh) 2019-05-17
CN107921003A (zh) 2018-04-17
HK1254343A1 (zh) 2019-07-19
EA201792591A1 (ru) 2018-06-29
EP3316869A1 (fr) 2018-05-09

Similar Documents

Publication Publication Date Title
MA50541A (fr) Formulations pharmaceutiques
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
MA42303A (fr) Formulations pharmaceutiques
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
EP3541385A4 (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
MA45187A (fr) Combinaisons pharmaceutiques
EP3603642A4 (fr) Préparation pharmaceutique
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
DK3199161T3 (da) Farmaceutisk præparat
EP3364945C0 (fr) Formulation solide
MA44987A (fr) Formulations de médicaments améliorées
EP3437644A4 (fr) Médicament
MA49837A (fr) Compositions pharmaceutiques
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
DK3280447T3 (da) Farmaceutiske formuleringer
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3646866A4 (fr) Préparation pharmaceutique
EP3527216A4 (fr) Médicament
EP3383371A4 (fr) Formulation pharmaceutique
DK3601277T3 (da) Farmaceutisk formulering
EP3395344A4 (fr) Médicament
HUE050881T2 (hu) Gyógyszerkészítmény
EP3528818A4 (fr) Compositions pharmaceutiques